Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Polymyxin b sulfate
Drug ID BADD_D01795
Description Polymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426]. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant[A176426]. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label]. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429].
Indications and Usage For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
Marketing Status Prescription; Discontinued
ATC Code A07AA05; J01XB02; S01AA18; S02AA11; S03AA03
DrugBank ID DB00781
KEGG ID D01066
MeSH ID D011112
PubChem ID 3083708
TTD Drug ID D09OOV
NDC Product Code 70860-124; 63323-321; 65897-2004; 63323-367; 45932-0001; 70860-103; 65897-1004; 49452-5600; 76003-0926; 55500-0008; 59838-002; 45932-0002; 38779-0045; 62991-3071; 70594-049; 54147-0006; 51552-0946; 68083-174; 54563-008; 51927-1086; 59838-101; 54147-0003; 45932-0018; 51551-0306; 51551-0305; 45932-0017
Synonyms Polymyxin B | Polymyxin B Sulfate | Aerosporin
Chemical Information
Molecular Formula C48H84N16O17S
CAS Registry Number 1404-26-8
SMILES CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCC(C(=O)NC(C(=O)NC(C(=O)N1)CC2=CC=CC=C2)C CN)NC(=O)C(CCN)NC(=O)C(CCO)NC(=O)C(CCN)NC=O)CCO)CCN)CCN.OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Albuminuria20.02.01.001--Not Available
Apnoea22.02.01.001--
Ataxia08.01.02.004; 17.02.02.001--
Azotaemia20.01.01.001--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
CSF protein13.07.02.006--Not Available
Cylindruria20.02.01.004--Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Meningism17.02.05.007--
Pain08.01.08.004--
Paraesthesia17.02.06.005--
Pyrexia08.05.02.003--
Somnolence19.02.05.003; 17.02.04.006--
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Musculoskeletal stiffness15.03.01.005--Not Available
Paraesthesia oral17.02.06.008; 07.05.03.003--Not Available
Nuchal rigidity15.05.04.005; 17.05.02.006--Not Available
The 1th Page    1    Total 1 Pages